Corona drug could be approved this year

The Braunschweig-based start-up Corat Therapeutics is currently testing its drug on patients. If all goes well, the company plans to apply for emergency approval before the end of the year.

Biopharma start-up Corat Therapeutics hopes to submit an application for provisional approval for a drug to treat Covid 19 disease later this year. The current development could lead to an application for emergency approval at the end of the year, the company's chief scientific officer, André Frenzel, told Deutsche Presse Agentur

At the end of April, the Braunschweig-based start-up announced that it was testing its drug COR-101 on sufferers in a clinical trial. The drug consists of monoclonal antibodies designed to help moderate and severe sufferers. 45 patients in five German cities are testing COR-101. "COR-101 is intended to be used to treat adult patients who have to be hospitalised because of COVID-19 and who may already require oxygen," said Helmut Salih, a physician from Tübingen and head of the study. "We are very confident that this study will be successful." The first results should be known in the summer.

Corat Therapeutics was founded in April 2020 as a spin-off of the biotech company Yumab with the aim of developing a corona drug. The company is financially supported by the Lower Saxony State Bank and private investors.